7月14日，Medline盘中下跌3.71%，报39.075美元/股，成交额1.16亿美元，延续近期跌势。
消息面上，公司此前因FDA连续发出两封警告信（涉及伊利诺伊州工厂成品药CGMP严重违规），并面临证券欺诈调查，监管风险持续发酵。公司需在规定时间内提交整改方案，否则可能面临暂停出口证书等进一步处罚。此外，自3月以来，黑石、凯雷、Hellman & Friedman及阿布扎比投资局关联股东已累计进行多轮大规模二级市场减持（合计超2亿股），持续增加市场抛压。同日医疗保健用品板块整体走弱，行业个股普遍承压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.